Profile data is unavailable for this security.
About the company
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
- Revenue in USD (TTM)1.91m
- Net income in USD-37.19m
- Incorporated2006
- Employees74.00
- LocationGenocea Biosciences Inc100 Acorn Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 876-8191
- Fax+1 (617) 876-8192
- Websitehttp://www.genocea.com/